Hydrochlorothiazide; losartan potassium - Generic Drug Details

What are the generic sources for hydrochlorothiazide; losartan potassium and what is the scope of patent protection?

Hydrochlorothiazide; losartan potassium is the generic ingredient in two branded drugs marketed by Organon, Alembic Pharms Ltd, Apotex, Aurobindo Pharma, Chartwell Rx, Granules, Hikma, Ipca Labs Ltd, Jubilant Cadista, Lupin Ltd, Macleods Pharms Ltd, Mylan, Prinston Inc, Teva Pharms, Torrent Pharms, Unichem, Watson Labs, and Zydus Pharms Usa Inc, and is included in eighteen NDAs. Additional information is available in the individual branded drug profile pages.

Thirty suppliers are listed for this compound.

Summary for hydrochlorothiazide; losartan potassium

US Patents:	0
Tradenames:	2
Applicants:	18
NDAs:	18
Finished Product Suppliers / Packagers:	30
Clinical Trials:	15
DailyMed Link:	hydrochlorothiazide; losartan potassium at DailyMed

Recent Clinical Trials for hydrochlorothiazide; losartan potassium

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Shanghai Jiao Tong University School of Medicine	Phase 4
Kyushu University	Phase 3
Agenzia Italiana del Farmaco	Phase 4

See all hydrochlorothiazide; losartan potassium clinical trials

Pharmacology for hydrochlorothiazide; losartan potassium

Drug Class	Angiotensin 2 Receptor Blocker Thiazide Diuretic
Mechanism of Action	Angiotensin 2 Receptor Antagonists
Physiological Effect	Increased Diuresis

Anatomical Therapeutic Chemical (ATC) Classes for hydrochlorothiazide; losartan potassium

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C09CA	Angiotensin II receptor blockers (ARBs), plain
C09C	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

Paragraph IV (Patent) Challenges for HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
HYZAAR	Tablets	hydrochlorothiazide; losartan potassium	100 mg/12.5 mg	020387	1	2006-04-04
HYZAAR	Tablets	hydrochlorothiazide; losartan potassium	50 mg/12.5 mg and 100 mg/25 mg	020387	1	2004-05-24

US Patents and Regulatory Information for hydrochlorothiazide; losartan potassium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Torrent Pharms	LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; losartan potassium	TABLET;ORAL	090528-002	Oct 6, 2010		DISCN	No	No
Hikma	LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; losartan potassium	TABLET;ORAL	077732-003	Oct 6, 2010		DISCN	No	No
Unichem	LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; losartan potassium	TABLET;ORAL	204832-003	Jul 21, 2017	AB	RX	No	No

Expired US Patents for hydrochlorothiazide; losartan potassium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-001	Apr 28, 1995	5,138,069*PED
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-002	Nov 10, 1998	5,608,075*PED
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387-003	Oct 20, 2005	5,153,197*PED

Hydrochlorothiazide; losartan potassium Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for Hydrochlorothiazide and Losartan Potassium?

Hydrochlorothiazide (HCTZ) and losartan potassium are established medications used to treat hypertension and heart failure. Together, their market encompasses a global value exceeding $17 billion annually, driven by high prescription volumes and expanding indications.

Hydrochlorothiazide Market Dynamics

Hydrochlorothiazide is among the most prescribed diuretics worldwide. It is utilized primarily for hypertension, edema, and fluid retention. The drug's global sales were approximately $4.2 billion in 2022, with a projected compound annual growth rate (CAGR) of 1-2% over the next five years (Source [1]).

Key Drivers:

• Generics penetration: Over 90% of HCTZ prescriptions are for generic formulations, reducing drug prices and profit margins but ensuring high accessibility.
• Prescriber familiarity: Long-standing use and extensive clinical validation sustain its prescription rates.
• Regulatory environment: Few regulatory hurdles limit approvals, but emerging concerns over efficacy compared to newer agents influence prescribing trends.

Challenges:

• Emerging safety concerns: Studies highlighting effects on glucose and lipid metabolism could restrict use in certain populations.
• Competition: Proliferation of fixed-dose combinations (FDCs) combining HCTZ with other antihypertensives shifts market dynamics.

Losartan Potassium Market Dynamics

Losartan, an angiotensin II receptor blocker (ARB), had sales reaching approximately $3.5 billion globally in 2022, with a forecasted CAGR of around 3% (Source [2]).

Key Drivers:

• Efficacy and safety: Compared with ACE inhibitors, losartan has a lower incidence of cough and angioedema.
• Expanding indications: Beyond hypertension, uses include diabetic nephropathy and heart failure.
• Patent expiration: Loss of patent exclusivity in numerous territories has propelled generic alternatives, intensifying price competition.

Challenges:

• Competition from newer ARBs: Drugs like olmesartan and valsartan offer similar efficacy with improved pharmacokinetics.
• Safety concerns: Recently, concerns over potential cancer risks associated with ARBs could impact perception and prescribing patterns.

Combination Therapy and Market Evolution

The combination of hydrochlorothiazide with losartan (e.g., Hyzaar) is popular, accounting for an estimated 15% of the antihypertensive market. The patent expiry of combination products is anticipated within the next 2-3 years.

How Are Regulatory Policies and Patent Landscapes Shaping Revenue?

Regulatory Environment

Regulatory agencies such as the FDA and EMA focus on safety monitoring; updates to prescribing guidelines have processed into clinical practices. The recent recalls or safety warnings have temporarily affected sales but didn't cause a substantial long-term dip.

Note: FDA’s relabeling efforts for hydrochlorothiazide regarding its minimal risk for skin cancer have not affected market stability significantly.

Patent and Exclusivity Status

Losartan’s first patent expired in 2012 in the U.S., opening global markets to generic producers. Despite the loss of exclusivity, branded versions maintain some market share through brand loyalty until newer agents or FDCs displace them.

Hydrochlorothiazide has had no relevant patents since the early 2000s, solidifying its status as a low-cost generic drug widely available.

What Is the Forecast for Financial Performance?

Revenue Projections

Drug	2022 Revenue	2028 Forecast	CAGR (2023-2028)	Key Influences
Hydrochlorothiazide	$4.2 billion	$4.5 billion	1-2%	Patent erosion, generic pricing, FDC competition
Losartan potassium	$3.5 billion	$3.6 billion	3%	Market saturation, newer ARBs, safety concerns

Profitability Trends

Profit margins for both drugs decline as generics dominate. Branded formulations see marginally higher margins, but overall, revenue growth remains modest.

Impacts of Biosimilar and Alternative Therapies

While biosimilars are primarily relevant to biologics, the generic landscape for small molecules like HCTZ and losartan predicates narrow profit margins. Innovations in drug delivery and combinational therapies could influence future revenue streams.

How Are Competitive and Patent Strategies Evolving?

Pharmaceutical companies focus on:

• Developing fixed-dose combinations involving HCTZ or losartan to extend lifecycle and enhance compliance.
• Seeking new indications or improved formulations to differentiate offerings.
• Leveraging patent challenges: Patent disputes over formulations or manufacturing processes aim to delay generic entry.

Summary

Hydrochlorothiazide and losartan potassium are core components of antihypertensive therapy with mature but stable markets. Revenue growth is constrained by patent expirations and price erosion but remains significant due to high prescribing rates. Market evolution hinges on combination therapies and emerging safety and efficacy data.

Key Takeaways

• Both drugs sustain high prescription volumes; generics dominate their markets.
• Patent expirations have led to increased competition and downward price pressures.
• New formulations, such as fixed-dose combinations, extend product lifecycle.
• Regulatory safety signals and emerging therapies influence future prescribing landscapes.
• Overall, moderate growth continues, with dynamics driven by competitive positioning and evolving clinical guidelines.

FAQs

1. How will patent expirations impact the future revenue of hydrochlorothiazide and losartan?

Patent expirations facilitate generic entry, reducing prices and profit margins. While volume remains high, revenue growth slows, and competition intensifies. Branded formulations may shift focus to value-added features to retain market share.

2. Are there upcoming alternative therapies replacing hydrochlorothiazide or losartan?

Newer antihypertensive classes, such as direct renin inhibitors and mineralocorticoid receptor antagonists, are gaining traction, but hydrochlorothiazide and losartan retain significant roles in treatment guidelines, especially in cost-sensitive settings.

3. How does safety data influence the market dynamics of these drugs?

Concerns over side effects or long-term safety can affect prescribing patterns, especially if new evidence suggests increased risks. Regulatory agencies may update labels, impacting sales.

4. What role do combination drugs play in the market?

Combination therapies, like losartan with hydrochlorothiazide, account for a substantial market share by enhancing patient adherence and treatment efficacy. Patent expiries of these combinations could influence sales strategies.

5. Are biosimilars relevant to these small-molecule drugs?

No. Biosimilars pertain to biologic drugs, whereas hydrochlorothiazide and losartan are small molecules with extensive generic markets. The focus remains on generics and FDC developments.

---

[1] IQVIA, 2022 Global Market Data
[2] EvaluatePharma, 2022 Reports